Merck, SML1443-25MG, L48H37

Application
L48H37 has been used as a myeloid differentiator protein 2 (MD2) antagonist/inhibitor:
to investigate intracellular signaling of LPS in signal transduction pathways via endosomic toll-like receptor 4 (TLR4) in colonic epithelium
to determine its anti-cancer effects in pancreatic ductal adenocarcinoma (PDAC)
to study its effects on lipopolysaccharide (LPS) and palmitate CC chemokine ligand 2 (CCL2) responses in normal kidney proximal tubule cells

Biochem/physiol Actions
L48H37 can stimulate apoptosis and prevent proliferation in pancreatic cancer cells, especially in the absence of histone-lysine N-methyltransferase 2D (KMT2D). It has an unsaturated monoketone structure, which helps to enhance its stability and anti-cancer effects. L48H37 may possess an anti-neoplastic effect on human pancreatic ductal adenocarcinoma (PDAC) cells.
L48H37 is a potent and chemically stable anti-inflammatory curcumin analog that inhibits LPS-induced inflammation through the myeloid differentiation 2 (MD-2) and toll-like receptor 4 (TLR4) complex. L48H37 is a potent MD2 inhibitor that binds to the hydrophobic region of MD-2 and blocks the interaction between MD2 and LPS. L48H37 significantly improves survival and protected lung injury in LPS-induced septic mice.
L48H37 is a potent and chemically stable anti-inflammatory curcumin analog.